You are here
- Home
Total number of clinical trials
- collapse Collection of efficacy and safety data of chinese patients who have received Faslodex 250mg treatmen
- collapse A Phase I/Ib, Multicentre, Study Comprising a Safety Run-In of AZD5363 When Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer; Followed by a Randomised Expansion of AZD5363 When Combined With Paclitaxel vs. Paclitaxel Plus Placebo in Patients With Estrogen Receptor (ER)-Positive Advanced or Metastatic Breast Cancer, Stratified by Phosphoinositide-3-kinase (PIK3CA) Mutation Status.
- collapse A non- interventional study to observe real life usage of atypical antipsychotics in the acute inpatient management of schizophrenia.
- collapse A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers
- collapse OPtimal Type 2 dIabetes Management Including benchmarking and Standard treatment in CEEMEA
- collapse Nexium capsules Hp Specific Clinical Experience Investigation
- collapse (OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia
- collapse A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
- collapse European Real Life Study on NSAIDs Treated Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS): Assessment of Pain Relieve, Gastrointestinal (GI) Symptoms, Adherence and Health Resource Consumption
- collapse A Phase I, Open-label, Randomised, 3-way Crossover Study to Demonstrate Bioequivalence of a Single Oral Dose of Naproxen Administered as VIMOVO Manufactured at AstraZeneca AB Compared to that of VIMOVO Manufactured by Patheon Pharmaceuticals and a Marketed Enteric-coated Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers
